Paul Billings was named chief medical officer and senior vice-president of medical affairs Natera, a company focused on non-invasive genetic testing and the analysis of circulating cell-free DNA.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
